| Dec'19 | Dec'18 | Dec'17 | ||||
|---|---|---|---|---|---|---|
Revenue: | ||||||
Total revenue | ||||||
21,219 | 27,508 | 2,872 | ||||
Grant revenue | ||||||
0 | 169 | 863 | ||||
Total revenue | ||||||
21,219 | 27,677 | 3,735 | ||||
Operating expenses: | ||||||
Research and development | ||||||
100,528 | 73,031 | 29,911 | ||||
General and administrative | ||||||
35,095 | 11,934 | 6,503 | ||||
Total operating expenses | ||||||
135,623 | 84,965 | 36,414 | ||||
Loss from operations | ||||||
-114,404 | -57,288 | -32,679 | ||||
Other income, net | ||||||
9,019 | 5,040 | 199 | ||||
Net loss | ||||||
-105,385 | -52,248 | -32,480 | ||||
Unrealized gain on marketable securities | ||||||
184 | -42 | - | ||||
Comprehensive loss | ||||||
-105,201 | -52,290 | -32,480 | ||||
Net loss per share, basic and diluted | ||||||
-1.71 | -4.62 | -3.55 | ||||
Shares used in computing net loss per share, basic and diluted | ||||||
61,734 | 11,302 | 9,142 | ||||